Physician profile
Sarah E Mayer
NPI 1477796589
$3,883.00
in general payments reported to CMS, 2019-2025
33 companies · $787 in 2025
The $787 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $886 · 2022: $1,017 · 2023: $734 · 2024: $460 · 2025: $787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,980.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,980.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $945.56 | 2021-2025 | |
| Novo Nordisk INC | $571.04 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $396.10 | 2021-2025 | |
| Amgen INC. | $218.98 | 2021-2025 | Otezla, Repatha, Repatha |
| Biohaven Pharmaceutical Holding Company LTD. | $203.90 | 2022 | |
| Lilly USA, LLC | $180.49 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Biohaven Pharmaceuticals, INC. | $164.57 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $153.72 | 2022-2025 | Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $136.18 | 2022-2023 | |
| Optinose US, INC. | $100.75 | 2021-2022 | |
| Glaxosmithkline, LLC. | $95.12 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $73.71 | 2025 | Caplyta |
| Jazz Pharmaceuticals INC. | $73.29 | 2021-2022 | |
| Abbott Laboratories | $57.84 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Dexcom, INC. | $51.80 | 2023-2024 | Dexcom G6 Transmitter |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $50.98 | 2021-2022 | |
| Shield Therapeutics INC | $49.00 | 2025 | |
| Idorsia Pharmaceuticals US INC | $37.03 | 2022-2023 | Quviviq |
| Merck Sharp & Dohme LLC | $34.65 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $33.73 | 2022-2025 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $31.46 | 2021-2022 | |
| Astellas Pharma US INC | $30.45 | 2023-2024 | Veozah, Myrbetriq |
| Vivus LLC | $19.61 | 2021 | |
| Exact Sciences Corporation | $19.37 | 2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $19.33 | 2022 | |
| Novartis Pharmaceuticals Corporation | $18.91 | 2023 | |
| Gilead Sciences, INC. | $18.85 | 2022 | |
| Hologic Sales and Service, LLC | $18.77 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $18.19 | 2022 | |
| Almatica Pharma LLC | $16.70 | 2021 | |
| Phadia US INC. | $16.43 | 2023 | Immunocap |
| Teva Pharmaceuticals USA, INC. | $14.13 | 2022 | |
| Adlon Therapeutics L.P. | $12.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Mayer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.